• Patchliner

    最高の実験柔軟性を誇るオートパッチ
  • Patchliner

    チップの自社内製造と厳格なQC
  • Patchliner

    10年以上のアッセイ系構築/サポート実績
  • Dynamite8

    Automated Dynamic Clamp
  • Patchliner

    マニュアルパッチの優位性を全て継承

2019 - MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo

icon pl   Patchliner publication in Cell Stem Cell (2019)

Authors:
Fiedler L.R., Chapman K., Xie M., Maifoshie E., Jenkins M., Golforoush P.A., Bellahcene M., Noseda M., Faust D., Jarvis A., Newton G., Paiva M.A., Harada M., Stuckey D.J., Song W., Habib J., Narasimham P., Aqil R., Schneider M.D.

Journal:
Cell Stem Cell (2019) https://doi.org/10.1016/j.stem.2019.01.013. [In Press, Corrected Proof] 


Highlights: 

  • Human iPSC-cardiomyocytes were used for MAP4K4 target validation and drug discovery
  • MAP4K4 shRNA protects hiPSC-cardiomyocytes from lethal oxidative stress
  • MAP4K4 inhibitors promote hiPSC-cardiomyocyte survival and function
  • MAP4K4 inhibition markedly reduces cardiac ischemia-reperfusion injury in mice

Summary:

Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival.


Download here

Back

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies).

You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.